SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Seattle Genetics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (Nasdaq: SGEN) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at

According to the Complaint, the Company announced that the U.S. Food and Drug Administration had enforced a clinical hold or partial clinical hold on initial stage trials of the Company's experimental cancer drug, vadastuximab talirine, to assess any possible risk of hepatotoxicity. The Company mentioned that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.

When this news was released to the public, the value of Seattle Genetics dropped, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125

Lundin Law PC